Anna Winkowski
May 2025
Anna
Winkowski
,
MS, MHA, BSN, RN, CCM, ACM
Industry
Oracle Cerner
Kansas City, MO
United States
She is passionate about ensuring that Oracle solutions yield better clinical outcomes and works tirelessly, both internally and directly with clients, to make this happen.
Anna meets all the criteria for the DAISY award and embodies the mission daily. She is passionate about ensuring that Oracle solutions yield better clinical outcomes and works tirelessly, both internally and directly with clients, to make this happen. The following story is one of many examples I could pull from her experiences over the past year.
Results...
Lovell FHCC is leveraging Oracle Health Registries to identify and contact Veterans who need lung cancer screenings. This has resulted in a 67% increase in panel identification and a 7% increase in screenings. This, in turn, is helping to identify Veterans with significant findings. The client states, "These efforts are driving early detection and better patient outcomes." Side note: This also happened as the department unexpectedly had a resignation. Amazing increase in productivity, along with an unplanned decrease in staff resources!
Anna's role in making this happen...
Just before FHCC went live, Anna worked with end users to identify a solution gap and then engaged proper VA stakeholders to gain national authorization. She continued to persist as she worked across Oracle solutions to modify Millennium and HDI solutions to accommodate the desired workflows. When the solutions were finally aligned with VA needs, she continued working with the leadership and end users to ensure solution and workflow adoption. She remains in contact with these users to monitor the evolution of the results and perpetuate the successes throughout the rest of VA.
Impact statement from VA employee...
"Since before going live at Lovell FHCC, we've worked to expand lung cancer screenings, growing from 864 to over 1,300 patients and sending nearly 600 letters to encourage scheduling,” said Susan Ruscheinsky, LCS coordinator at Lovell FHCC. “Post-holidays, referrals have risen to 10 per day, and we're booked through mid-March [2025]. Using the LCS Patient List from Registries, we've increased our screening rate from 35% to 42%. In December, we identified two patients with significant findings, which are now in the diagnostic stage. These efforts are driving early detection and better patient outcomes.”
Results...
Lovell FHCC is leveraging Oracle Health Registries to identify and contact Veterans who need lung cancer screenings. This has resulted in a 67% increase in panel identification and a 7% increase in screenings. This, in turn, is helping to identify Veterans with significant findings. The client states, "These efforts are driving early detection and better patient outcomes." Side note: This also happened as the department unexpectedly had a resignation. Amazing increase in productivity, along with an unplanned decrease in staff resources!
Anna's role in making this happen...
Just before FHCC went live, Anna worked with end users to identify a solution gap and then engaged proper VA stakeholders to gain national authorization. She continued to persist as she worked across Oracle solutions to modify Millennium and HDI solutions to accommodate the desired workflows. When the solutions were finally aligned with VA needs, she continued working with the leadership and end users to ensure solution and workflow adoption. She remains in contact with these users to monitor the evolution of the results and perpetuate the successes throughout the rest of VA.
Impact statement from VA employee...
"Since before going live at Lovell FHCC, we've worked to expand lung cancer screenings, growing from 864 to over 1,300 patients and sending nearly 600 letters to encourage scheduling,” said Susan Ruscheinsky, LCS coordinator at Lovell FHCC. “Post-holidays, referrals have risen to 10 per day, and we're booked through mid-March [2025]. Using the LCS Patient List from Registries, we've increased our screening rate from 35% to 42%. In December, we identified two patients with significant findings, which are now in the diagnostic stage. These efforts are driving early detection and better patient outcomes.”